Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Avammune Therapeutics

Request full access

Biotech company developing multi-modal cancer therapies, including ADAR1 and ENPP1 inhibitors and radioligand therapeutics for solid tumors

Philadelphia, United StatesFounded 2019Biotech & Life Sciences

About Avammune Therapeutics

Avammune Therapeutics is an R&D-driven drug discovery company developing next-generation oncology therapies for hard-to-treat solid tumors. The company combines multiple therapeutic modalities: an ADAR1 p150 inhibitor (AVA ADR 001), an orally available ENPP1 inhibitor (AVA NP 695), and a radioligand therapeutic in development. AVA ADR 001 is a small-molecule inhibitor of ADAR1 that modulates the innate immune system, with preclinical data showing an interferon response via an MDA5-dependent mechanism, selectivity for the p150 isoform, and anti-tumor efficacy in the B16F10 melanoma syngeneic mouse model, including synergy when combined with anti-PD1 therapy. AVA NP 695 is an ENPP1 inhibitor advancing toward IND-enabling studies. The company was founded by serial biotech entrepreneurs previously behind Aten Porus Lifesciences and Oraxion Therapeutics, and is backed by investors including Shastra VC, Capital 2B, IvyCap Ventures, 1Crowd, Kotak Alternate Asset Managers and The Chennai Angels. Avammune is headquartered in Philadelphia, with an R&D affiliate in Bangalore, India.

Source: Dealroom company data

At a glance

Status
Operational
Employees
22
Open positions
None listed
Dealroom signal
58.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC May 2025 $12M $48M IvyCap Ventures · 1Crowd · Capital 2B · Shastra VC ↗
LATE VC✓Equity / VC Jul 2022 $0 — The Chennai Angels ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Avammune Therapeutics website traffic

Latest recorded traffic for Avammune Therapeutics is 1.1K monthly website visits, up 96.4% over the last three months. Avammune Therapeutics's team grew 120% over the past year.

Latest monthly visits1.1K 3-month web change+96.4% 1-year team growth+120%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Avammune Therapeutics in the Philadelphia ecosystem

Live from Dealroom

The Avammune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Capital 2B
  • Shastra VC
  • IvyCap Ventures
  • 1Crowd
  • Kotak Alternate Asset Managers

Series B and later1 investor entered at this stage

  • The Chennai Angels
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇮🇳 India100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Avammune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Avammune Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.